Ikena Oncology, Inc. — FY2022 Form 10-K
Entity note: The request identifies Imagenebio, Inc., but the supplied filing is for Ikena Oncology, Inc. (Nasdaq: IKNA). This is the annual report for the fiscal year ended December 31, 2022, filed March 14, 2023—not a standalone fourth-quarter report.
Business context
Ikena is a clinical-stage oncology company developing biomarker-targeted medicines. Its principal programs target the Hippo pathway (IK-930), the RAS pathway (IK-595), and immune signaling (IK-175, partnered with Bristol Myers Squibb, or BMS). The company had no approved products and no product-sales revenue.
Financial results and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Collaboration revenue | $15.6 million | $31.0 million | Down $15.4 million, or 50% |
| Research and development expense | $64.3 million | $47.1 million | Up $17.2 million, or 37% |
| General and administrative expense | $22.2 million | $18.0 million | Up $4.2 million, or 23% |
| Operating loss | $70.9 million | $34.1 million | Loss increased |
| Net loss | $68.8 million | $34.1 million | Loss increased by $34.7 million |
| Net loss per share | $1.90 | $1.22 | Loss per share increased |
Collaboration revenue was from the BMS agreement; Ikena reported no product-sales revenue. The revenue decline primarily reflected a prior-year change in estimated IK-412 services, including a $16.5 million revenue catch-up recognized in 2021 after the program was paused outside committed manufacturing work.
At December 31, 2022, cash and cash equivalents were $59.9 million and marketable securities were $97.0 million, totaling $156.9 million. Operating cash use was $74.1 million; investing cash use was $99.3 million, primarily reflecting purchases of marketable securities; financing provided $1.1 million. The company reported no borrowings in the supplied financial statements. Operating lease liabilities totaled $5.7 million, including $1.9 million current. Accumulated deficit was $214.2 million.
Management estimated available cash, cash equivalents and marketable securities would fund planned operations into 2025; the filing cautions this estimate depends on assumptions and may prove inaccurate. There is no clear gross-margin or operating-margin measure relevant to product sales because the company had no commercial products.
Material changes and program updates
- IK-930 entered Phase 1 dosing in January 2022. FDA granted orphan drug designation for mesothelioma and fast track designation for unresectable NF2-deficient mesothelioma. Initial monotherapy data were expected in the second half of 2023; Ikena also planned an osimertinib combination cohort with AstraZeneca.
- IK-595 was nominated as a development candidate in November 2022. Ikena planned an IND submission in the second half of 2023; its differentiation and potential therapeutic-window advantages were preclinical hypotheses, not demonstrated clinical benefits.
- IK-175 Phase 1 data presented in November 2022 showed, in a 10-patient urothelial carcinoma combination expansion cohort, a 20% overall response rate and 40% disease control rate. The corresponding 10-patient monotherapy cohort reported a 10% response rate and 20% disease control rate. Results were preliminary and based on small cohorts; the study continued.
- Ikena discontinued its IK-007 MSS colorectal cancer development in November 2022 after the study did not meet predefined antitumor activity criteria; investigator-initiated programs continued. IK-412 development was paused after manufacturing delays, with committed CMC work completed in 2022.
Outlook, risks and unusual items
The company expected substantial ongoing R&D spending and operating losses, with additional capital likely required. It had an effective shelf registration for up to $300 million and an ATM program for up to $100 million; no ATM sales had occurred as of the filing. BMS could elect to license IK-175 for a $50 million fee, with potential milestone payments and royalties; these amounts were contingent, not assured. The IK-412 option fee was $40 million under the agreement, but that program was paused.
Key risks include clinical and regulatory failure, uncertainty in early or preliminary data, limited patient populations and enrollment challenges, reliance on CROs and single-source suppliers, dependence on future financing, competition, and patent and reimbursement uncertainty. The filing also cites potential effects from COVID-19, inflation, capital-market disruption, and geopolitical events. No material litigation was reported. The auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting, but the auditor did not attest to internal-control effectiveness under the emerging-growth-company exemption.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-K is Ikena Oncology, not Imagenebio.
- Check subsequent clinical updates and whether the reported IK-175 response and disease-control results were confirmed in larger or later-stage cohorts.
- Track IK-930 trial progress, safety, dose selection, and whether planned combination studies proceeded.
- Verify IK-595 IND timing and clinical initiation against subsequent filings; the 2023 timeline was forward-looking.
- Monitor cash burn, marketable-security liquidity, financing activity, and the assumptions underlying the stated runway into 2025.
- Review BMS option status and any changes to IK-175 or IK-412 collaboration rights and potential payments.